Publications dans lesquelles il/elle collabore avec Francisco Ignacio Aranda López (18)

2020

  1. Microglandular adenosis of the breast in a patient with a history of mediastinal radiotherapy

    Revista Espanola de Patologia, Vol. 53, Núm. 4, pp. 254-256

2017

  1. CD44 induces FOXP3 expression and is related with favorable outcome in breast carcinoma

    Virchows Archiv, Vol. 470, Núm. 1, pp. 81-90

2015

  1. Osteopontin regulates VEGFA and ICAM-1 mRNA expression in breast carcinoma

    American Journal of Clinical Pathology

2014

  1. Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence

    Human Pathology

2013

  1. Prevalence of Lynch syndrome among patients with newly diagnosed endometrial cancers

    PLoS ONE, Vol. 8, Núm. 11

2012

  1. Adenocarcinoma y tumor carcinoide pulmonares sincrónicos. Presentación de dos casos

    Revista Espanola de Patologia, Vol. 45, Núm. 1, pp. 29-34

2011

  1. Increased insulin-like growth factor-1 receptor mRNA expression predicts poor survival in immunophenotypes of early breast carcinoma

    Modern Pathology, Vol. 24, Núm. 2, pp. 201-208

2010

  1. Adjuvant docetaxel for high-risk, node-negative breast cancer

    New England Journal of Medicine, Vol. 363, Núm. 23, pp. 2200-2210

  2. Neoadyuvancia en cáncer de mama: Papel del patólogo

    Revista Espanola de Patologia

  3. Papel de "pituitary tumour-transforming gene (PTTG)" en los adenomas hipofisarios

    Endocrinología y nutrición: órgano de la Sociedad Española de Endocrinología y Nutrición, Vol. 57, Núm. 1, pp. 28-34

  4. Papel de pituitary tumour-transforming gene (PTTG) en los adenomas hipofisarios

    Endocrinologia y Nutricion, Vol. 57, Núm. 1, pp. 28-34

2009

  1. Low activation of Insulin-like Growth Factor 1-Receptor (IGF1R) is associated with local recurrence in early breast carcinoma

    Breast Cancer Research and Treatment, Vol. 117, Núm. 2, pp. 433-441

2008

  1. Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas

    Virchows Archiv, Vol. 453, Núm. 2, pp. 133-139

2007

  1. Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: prognostic relevance

    Human Pathology, Vol. 38, Núm. 1, pp. 26-34

  2. Prognostic implications of HER-2 status in steroid receptor-positive, lymph node-negative breast carcinoma

    American Journal of Clinical Pathology, Vol. 127, Núm. 5, pp. 780-786

2005

  1. Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas

    Human Pathology, Vol. 36, Núm. 10, pp. 1090-1095

2004

  1. Defective mismatch-repair colorectal cancer: Clinicopathologic characteristics and usefulness of immunohistochemical analysis for diagnosis

    American Journal of Clinical Pathology, Vol. 122, Núm. 3, pp. 389-394

  2. Oncocytic transformation in pituitary adenomas: Immunohistochemical analyses of 65 cases

    Archives of Pathology and Laboratory Medicine, Vol. 128, Núm. 7, pp. 776-780